Cyprotex, wholly owned by Evotec , is a leading company specializing in predictive toxicology and ADME-PK services. The company was established in 1999 and works with more than 1,500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including cell-based assays, in silico models and databases to predict how a new drug will be processed in the human body and what effects it might have on the body.
Evotec Purpose & Vision
Unleashing innovation in drug discovery to develop life-changing medicines
We are pioneering drug discovery and development, leveraging cutting-edge technology, disruptive science, and AI-driven innovation. Together with our partners, we accelerate the journey from concept to cure.
